Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool

Matsuda, Yuichi; Okita, Kenji; Furuhata, Tomohisa; Kutomi, Goro; Yamashita, Kentaro; Sato, Yasushi; Takimoto, Rishu; Hirata, Koichi

doi:10.1007/s00520-015-2780-z

Cited by 4 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13) Meanwhile, MAT, a patient self-reporting questionnaire, has been developed by MASCC and is expected to provide a convenient and supportive tool for clinician evaluations of acute and delayed nausea and/or vomiting. 5) A positive correlation in the severity scale between the patient diary and MAT was observed in patients with solid tumors, whereas the concordance rate between the physician assessments and patient descriptions was relatively low. 6) To our knowledge, the present study is the first report on the comparison of the CINV severity scores between CTCAE and MAT for only patients with hematological malignancies.…”

Section: Discussionmentioning

confidence: 93%

“…The MAT has been validated in outpatients with solid tumors in the United Kingdom and United States of America, 5) Japan, 6) and China. 7) The reports from America 5) and China 7) found a strong positive correlation between the Rhodes Index for Nausea, Vomiting, and Retching (INVR), as a patient's diary, with the reliability and effectiveness of MAT records for solid tumors. The report from Japan 6) showed a strong positive correlation between the patient's diary and MAT records.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Comparative Quantification of Chemotherapy-Induced Nausea and Emesis between the Common Terminology Criteria for Adverse Events and the Multinational Association of Supportive Care in Cancer Antiemesis Tool

Uchida

Nakamura

Shima

et al. 2018

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Chemotherapy-induced nausea and vomiting (CINV) are generally evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE). The Multinational Association for Supportive Care in Cancer (MASCC) developed the MASCC Antiemesis Tool (MAT) to facilitate recognition for CINV between patients and oncology specialists. In the present study, MAT and CTCAE were comparatively assessed in Japanese patients with hematological malignancies. A total of 61 patients were eligible for this study. The CTCAE data were collected from an electronic medical record system. The patients were asked to complete the Japanese version of MAT in the hospital, on the first and fourth days after the start of chemotherapy. The percentages of patients in whom nausea was completely controlled, with severity scores of zero, ranged from 70.5 to 82.0% for CTCAE and from 59.0 to 75.4% for MAT, during the first five days after the chemotherapy. The percentages of patients who had no vomiting ranged from 93.4 to 96.7% for CTCAE and from 90.2 to 98.4% for MAT. During the observation periods, the day-today response profiles of patients who received antiemetic treatment were comparable between CTCAE and MAT cohorts, and these two assessment tools showed good, positive correlations for nausea severity scores. The present study shows that the MAT is a useful tool for assessing the severity of CINV in patients with hematological malignancy, is comparable to CTCAE, and facilitates the identification of poor cancer care conditions by medical staff.

show abstract

Section: Discussionmentioning

confidence: 93%

mentioning

confidence: 99%

Comparative Quantification of Chemotherapy-Induced Nausea and Emesis between the Common Terminology Criteria for Adverse Events and the Multinational Association of Supportive Care in Cancer Antiemesis Tool

Uchida

Nakamura

Shima

et al. 2018

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…MASCC Antiemetic evaluation tool table (MAT): This tool was used to assess the occurrence of acute CINV (completed on day 4 of chemotherapy) and delayed CINV (completed on day 8 of chemotherapy) in patients ( 9 ). Patients who did not experience vomiting and/or significant nausea and had no record of rescue antiemetic were classified as “no CINV”; their family caregivers were assigned to No-CINV group.…”

Section: Methodsmentioning

confidence: 99%

Chemotherapy induced nausea and vomiting may cause anxiety and depression in the family caregivers of patients with cancer

Luo,

Yang,

Chen

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

ObjectiveTo investigate the impact of chemotherapy induced nausea and vomiting (CINV) on the anxiety and depression of the primary family caregivers of patients with cancer.MethodsThis study screened family caregivers of patients with cancer undergoing highly emetogenic chemotherapy (HEC) containing a 3-day cisplatin regime. Caregivers who did not experience anxiety or depression at baseline screening were enrolled in this study. Based on the patients’ CINV status during chemotherapy, their family caregivers were divided into two groups: patients who experienced CINV (CINV group) and patients who did not experience CINV (No-CINV group). All enrolled family caregivers completed the Hospital Anxiety and Depression Scale (HADS) questionnaire on the fourth and 8 days of chemotherapy.ResultsA total of 256 family caregivers were screened for this study, of which 195 caregivers without anxiety or depression at baseline were included. A total of 150 (76.9%) patients undergoing chemotherapy experienced acute CINV; 63 (42%) of their family caregivers experienced anxiety, and 65 (43.3%) developed depression. This was significantly higher than the experiences of the No-CINV group (2.2%, P < 0.001; 0%, P < 0.001, respectively). Among the patients undergoing chemotherapy, 86 (44.1%) experienced delayed CINV. The incidence of anxiety and depression in the family caregivers of patients with delayed CINV were 27.9 and 36%, respectively, both of which were significantly higher than that in the family caregivers of the No-CINV group (0.9%, P < 0.001; and 0.9%, P < 0.001, respectively).ConclusionAcute and delayed CINV occurring in patients during chemotherapy may induce anxiety and depression in their family caregivers.

show abstract

Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study

Mukhopadhyay

Kwatra

et al. 2016

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool

Abstract: The results of the study showed that the Japanese version of MAT is a highly reliable tool for CINV assessment, indicating that it is valid for assessing CINV in outpatients.

Cited by 4 publications

References 27 publications

Comparative Quantification of Chemotherapy-Induced Nausea and Emesis between the Common Terminology Criteria for Adverse Events and the Multinational Association of Supportive Care in Cancer Antiemesis Tool

Comparative Quantification of Chemotherapy-Induced Nausea and Emesis between the Common Terminology Criteria for Adverse Events and the Multinational Association of Supportive Care in Cancer Antiemesis Tool

Chemotherapy induced nausea and vomiting may cause anxiety and depression in the family caregivers of patients with cancer

Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study

Contact Info

Product

Resources

About